Moderna begins first human trial of Bundibugyo Ebola vaccine
Summary
Moderna said it plans to make at least 500,000 doses available to low- and middle-income countries at access pricing under its agreement with CEPI
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For India, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketIndia
- ImpactMedium (50/100)
- SignalNews